SBBP Strongbridge Biopharma plc - Or

2.40
-0.1  -4%
Previous Close 2.50
Open 2.55
Price To book 0.88
Market Cap 50.89M
Shares 21,205,000
Volume 70,267
Short Ratio 0.50
Av. Daily Volume 50,636

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment from second trial to begin mid-2017 with top-line data expected in 3Q 2018.
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 top-line data due 1Q 2018.
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome

Latest News

  1. Strongbridge Biopharma plc Expands Commercial Capabilities with Two Rare Disease Executive Hires
  2. Strongbridge Biopharma plc Announces Closing of $35 Million Equity Financing and $40 Million Credit Facility
  3. Post Earnings Coverage as Strongbridge Loss Narrowed; Acquires US Rights for KEYEVIS and Announced Equity Financing
  4. Strongbridge Biopharma plc to Present at Biotech Showcase 2017
  5. Strongbridge Biopharma plc to Present at Biotech Showcase 2017
  6. $35M infusion: Bucks County biopharm firm reaches funding deal
  7. Strongbridge Biopharma plc Announces Closing of $35 Million Equity Financing and $40 Million Credit Facility
  8. Strongbridge Biopharma plc Announces Closing of $35 Million Equity Financing and $40 Million Credit Facility
  9. Stonebridge Biopharma raises $35 million by selling shares at a deep discount
  10. Strongbridge Biopharma plc Announces $35 Million Equity Financing
  11. Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS® From Taro
  12. Strongbridge Biopharma plc Provides Corporate and Financial Update
  13. Strongbridge Biopharma plc Provides Corporate and Financial Update
  14. Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS® From Taro
  15. Strongbridge Biopharma plc Announces $35 Million Equity Financing
  16. Strongbridge Biopharma plc Announces Promotion of Fredric Cohen, M.D., to Chief Medical Officer
  17. Strongbridge Biopharma plc Announces Appointment of Jeffrey W. Sherman, M.D., FACP, to Board of Directors
  18. Strongbridge Biopharma (SBBP) Jumps: Stock Moves Up 5.5%
  19. Strongbridge Biopharma plc Announces Presentation at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
  20. Strongbridge Biopharma plc to Participate in the JMP Securities Life Sciences Conference and 3rd Annual ROTH Healthcare Day in London